Kazia Therapeutics (KZIA) Capital Expenditures (2016)

Kazia Therapeutics' (KZIA) quarterly Capital Expenditures came in at -$6997.5 in Q4 2016.

Kazia Therapeutics (KZIA) Capital Expenditures (2016) Analysis & Trends

Kazia Therapeutics (KZIA) has 1 years of Capital Expenditures data on file, last reported at -$6997.5 in Q4 2016.

Quarterly Capital Expenditures changed N/A year-over-year to -$6997.5 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$478997.5 (changed N/A YoY) and the FY2017 annual result came in at $9048.8, down 97.62% from the prior year.
Capital Expenditures was little changed at -$6997.5 in Q4 2016.
In the past five years, Capital Expenditures ranged from a high of -$6997.5 in Q4 2016 to a low of -$6997.5 in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Kazia Therapeutics	4.22 Bn	4.22 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	-6,997.48
Dec 31, 2016	-6,997.48